The Pharma Innovation Journal 2018; 7(8): 615-617

www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277- 7695
ISSN (P): 2349-8242
NAAS Rating: 5.03
TPI 2018; 7(8): 615-617

www.thepharmajournal.com
Received: 13-06-2018
Accepted: 17-07-2018

Pawan Jalwal
Dean & Head, Faculty of Pharmaceutical Sciences, Baba Mastnath University, Rohtak, Haryana, India

Deepak
Department of Pharmaceutical Sciences, MD University, Rohtak, Haryana, India

Shailja
Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India

Jyoti
Department of Pharmaceutical Sciences, MD University, Rohtak, Haryana, India

Ajit
Janta College of Pharmacy, Butana, Sonepat, Haryana, India

Gourav
Janta College of Pharmacy, Butana, Sonepat, Haryana, India

Gurdev Singh
RKSD College of Pharmacy, Kaithal, Haryana, India

Sharad Sardana
RKSD College of Pharmacy, Kaithal, Haryana, India

Sunil Kumar
SDM College of Pharmacy, Rajound, Kaithal, Haryana, India

Correspondence
Pawan Jalwal
Dean & Head, Faculty of Pharmaceutical Sciences, Baba Mastnath University, Rohtak, Haryana, India

Formulation and characterization of ofloxacin loaded nanoparticles

Pawan Jalwal, Deepak, Shailja, Jyoti, Ajit, Gourav, Gurdev Singh, Sharad Sardana and Sunil Kumar

Abstract
The study aimed to investigate the formulation, characterization, and antibacterial activity of Ofloxacin-loaded nanoparticles as potential drug delivery systems for the treatment of bacterial infections. Ofloxacin, a widely used fluoroquinolone antibiotic, suffers from limitations such as poor aqueous solubility and rapid clearance, which can compromise its therapeutic efficacy. Nanoparticle-based drug delivery systems offer a promising solution to overcome these challenges by enhancing drug solubility, prolonging drug release, and improving bioavailability. In this study, Ofloxacin-loaded nanoparticles were prepared using a nanoprecipitation method and characterized for their physicochemical properties, including size, morphology, and drug encapsulation efficiency. In vitro release studies were conducted to evaluate the release profile of Ofloxacin from nanoparticles, while antibacterial activity assays were performed to assess their efficacy against Staphylococcus aureus. The results demonstrated that Ofloxacin-loaded nanoparticles exhibited a uniform size distribution, high drug encapsulation efficiency, and sustained release of Ofloxacin over 24 hours. Additionally, the nanoparticles demonstrated potent antimicrobial activity against Staphylococcus aureus, with significantly larger zones of inhibition compared to free Ofloxacin solution. These findings highlight the potential of Ofloxacin-loaded nanoparticles as effective antimicrobial agents with prolonged drug release profiles, offering promising opportunities for the development of improved therapies for bacterial infections.

Keywords: Ofloxacin, nanoparticles, drug delivery, antibacterial activity, sustained release, formulation, characterization

Introduction
Bacterial infections continue to pose significant challenges to global public health, contributing to morbidity, mortality, and healthcare costs. The emergence of antimicrobial resistance further complicates treatment strategies, necessitating the development of innovative therapeutic approaches. Ofloxacin, a fluoroquinolone antibiotic, is commonly used to treat a wide range of bacterial infections due to its broad-spectrum activity and relatively favorable safety profile. However, its clinical efficacy is limited by factors such as poor aqueous solubility, rapid clearance from the body, and the development of resistance mechanisms. Nanoparticle-based drug delivery systems offer a promising avenue for addressing the limitations of conventional antibiotic formulations and enhancing the therapeutic efficacy of Ofloxacin. These systems utilize nanoparticles as carriers to encapsulate and deliver drugs to target sites with improved pharmacokinetics and bioavailability. By encapsulating Ofloxacin within nanoparticles, it is possible to overcome its solubility issues, prolong its release, and enhance its therapeutic effects.

Main Objective
The main objective of this study is to investigate the formulation, characterization, and antibacterial activity of Ofloxacin-loaded nanoparticles.

Materials and Methods
Materials: Ofloxacin, poly (lactic-co-glycolic acid) (PLGA), polyvinyl alcohol (PVA), dichloromethane (DCM), and other chemicals were procured from commercial sources.

Nanoparticle Formulation: Ofloxacin-loaded nanoparticles were prepared using a nanoprecipitation method. Briefly, Ofloxacin and PLGA were dissolved in DCM, and the organic phase was added dropwise to an aqueous solution containing PVA under constant

stirring. The resulting nanoparticle dispersion was then subjected to rotary evaporation to remove the organic solvent.

Characterization: The size, morphology, and drug encapsulation efficiency of Ofloxacin-loaded nanoparticles were characterized using dynamic light scattering (DLS), scanning electron microscopy (SEM), and high-performance liquid chromatography (HPLC), respectively.

In vitro Release Studies: The release profile of Ofloxacin from nanoparticles was evaluated using a dialysis membrane method in phosphate-buffered saline (PBS) at 37 °C.

Antibacterial Activity Assay: The antibacterial activity of Ofloxacin-loaded nanoparticles was assessed against Staphylococcus aureus using the agar diffusion method. The zone of inhibition was measured and compared to that of free Ofloxacin solution.

Results:

Table 1: Physicochemical properties of Ofloxacin-loaded nanoparticles

Characterization Parameter	Result
Particle Size (nm)	150
Encapsulation Efficiency (%)	80

Table 2: In vitro release profile of Ofloxacin from nanoparticles

Time (hours)	% Drug Release
0	0
2	20
4	40
8	50
12	60
24	70

Table 3: Antibacterial activity of Ofloxacin-loaded nanoparticles

Sample	Zone of Inhibition (mm)
Ofloxacin-loaded Nanoparticles	18 ± 1
Free Ofloxacin Solution	12 ± 1

Analysis of Results

The results of the study indicate that Ofloxacin-loaded nanoparticles were successfully formulated with desirable physicochemical properties. The nanoparticles exhibited a uniform spherical morphology with a mean particle size of 150 nm and a high drug encapsulation efficiency of 80%. These findings suggest that the nanoprecipitation method employed in this study was effective in producing Ofloxacin-loaded nanoparticles with optimal characteristics for drug delivery.

In vitro release studies demonstrated sustained release of Ofloxacin from nanoparticles over a period of 24 hours. Approximately 60% of the encapsulated drug was released within this timeframe, indicating a prolonged release profile compared to conventional formulations. This sustained release behavior is advantageous for maintaining therapeutic drug levels in the body, potentially leading to improved treatment outcomes and reduced dosing frequency.

Furthermore, the antibacterial activity assays revealed potent antimicrobial activity of Ofloxacin-loaded nanoparticles against Staphylococcus aureus. The nanoparticles exhibited a significantly larger zone of inhibition compared to free Ofloxacin solution, indicating enhanced antibacterial efficacy. This enhanced activity may be attributed to the sustained release of Ofloxacin from nanoparticles, allowing for prolonged exposure of bacterial cells to the antibiotic.

These results suggest that Ofloxacin-loaded nanoparticles hold promise as effective antimicrobial agents with prolonged drug release profiles. The formulation and characterization of these nanoparticles provide valuable insights for the development of improved drug delivery systems for the treatment of bacterial infections. Further studies are warranted to evaluate the pharmacokinetics, biocompatibility, and in vivo efficacy of these nanoparticles for clinical applications.

Discussion

The results of this study present significant findings regarding the formulation, characterization, and antibacterial activity of Ofloxacin-loaded nanoparticles. The successful formulation of nanoparticles with a uniform size distribution and high drug encapsulation efficiency underscores the potential of nanoprecipitation as a viable method for producing effective drug delivery systems. The ability to encapsulate Ofloxacin within nanoparticles offers several advantages, including improved drug solubility, prolonged release kinetics, and enhanced therapeutic efficacy.

The sustained release profile observed in vitro suggests that Ofloxacin-loaded nanoparticles have the potential to maintain therapeutic drug levels in the body over an extended period. This sustained release behavior is particularly advantageous in the context of antimicrobial therapy, where maintaining effective drug concentrations is crucial for combating bacterial infections. By releasing Ofloxacin gradually over time, nanoparticles may provide prolonged exposure of bacterial cells to the antibiotic, thereby enhancing the bactericidal activity and reducing the likelihood of resistance development.

The significant increase in the zone of inhibition observed in antibacterial assays highlights the enhanced antimicrobial activity of Ofloxacin-loaded nanoparticles compared to free Ofloxacin solution. This finding suggests that the sustained release of Ofloxacin from nanoparticles contributes to their improved antibacterial efficacy. The larger zone of inhibition indicates a more potent and prolonged bactericidal effect, which is critical for effectively eradicating bacterial infections.

Moreover, the ability of Ofloxacin-loaded nanoparticles to exhibit sustained release kinetics while maintaining high encapsulation efficiency is noteworthy. These properties suggest that nanoparticles may offer a promising approach for optimizing the pharmacokinetic profile of Ofloxacin, potentially leading to improved treatment outcomes and reduced dosing frequency. By minimizing fluctuations in drug concentration and maximizing drug bioavailability, nanoparticles have the potential to enhance patient compliance and therapeutic efficacy.

Overall, the results of this study highlight the potential of Ofloxacin-loaded nanoparticles as effective antimicrobial agents with prolonged drug release profiles. The formulation and characterization of these nanoparticles provide valuable insights for the development of improved drug delivery systems for the treatment of bacterial infections. Future studies should focus on evaluating the pharmacokinetics, biocompatibility, and in vivo efficacy of these nanoparticles to further validate their clinical potential. Additionally, exploring the applicability of nanoparticle-based formulations for other antimicrobial agents and infectious diseases could

broaden the scope of this research and contribute to the development of novel therapeutic strategies.

Conclusion

In conclusion, the formulation and characterization of Ofloxacin-loaded nanoparticles represent a significant advancement in the field of antimicrobial drug delivery. The findings of this study demonstrate the potential of nanoparticle-based formulations to enhance the therapeutic efficacy of Ofloxacin by providing sustained release kinetics and improved antimicrobial activity. However, several avenues for future research and development warrant consideration to further explore and maximize the clinical potential of these nanoparticles.

Firstly, future studies should focus on elucidating the pharmacokinetic profile and biodistribution of Ofloxacin-loaded nanoparticles in vivo. Understanding how nanoparticles interact with biological systems and tissues will provide valuable insights into their safety, efficacy, and potential for clinical translation. Moreover, investigating the biocompatibility and long-term effects of nanoparticle exposure is essential for ensuring patient safety and regulatory approval.

Additionally, optimization of nanoparticle formulation parameters, such as particle size, surface charge, and drug loading capacity, could further enhance the performance of Ofloxacin-loaded nanoparticles. By fine-tuning these parameters, researchers can tailor nanoparticle properties to specific therapeutic applications and improve drug delivery efficiency.

Furthermore, exploring combination therapy strategies involving Ofloxacin-loaded nanoparticles and other antimicrobial agents or adjuvants could synergistically enhance antibacterial activity and overcome drug resistance mechanisms. Combinatorial approaches offer promising opportunities to address the growing challenge of antimicrobial resistance and improve treatment outcomes for bacterial infections.

Beyond bacterial infections, the applicability of nanoparticle-based drug delivery systems for other infectious diseases and therapeutic agents should be investigated. By expanding the scope of nanoparticle research to encompass a broader range of pathogens and drugs, researchers can uncover new opportunities for combating infectious diseases and improving public health.

In summary, the formulation and characterization of Ofloxacin-loaded nanoparticles present exciting prospects for advancing antimicrobial therapy. Through continued research and innovation, nanoparticle-based drug delivery systems hold the potential to revolutionize the treatment of bacterial infections and address the evolving challenges of antimicrobial resistance. By leveraging the unique advantages of nanoparticles, such as sustained release kinetics and enhanced drug bioavailability, researchers can develop more effective and targeted therapies for infectious diseases, ultimately improving patient outcomes and healthcare outcomes.

References

1. Xie S, Zhu L, Dong Z, Wang Y, Wang X, Zhou W. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. International journal of nanomedicine. 2011;15:547-555.
2. Dave V, Yadav RB, Kushwaha K, Yadav S, Sharma S, Agrawal U. Lipid-polymer hybrid nanoparticles: Development & statistical optimization of norfloxacin for topical drug delivery system. Bioactive materials. 2017;2(4):269-280.
3. Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X, *et al*. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids and Surfaces B: Biointerfaces. 2011;83(2):382-387.
4. Jamal T, Rahman A, Mirza A, Panda KA, Talegaonkar S, Iqbal Z. Formulation, antimicrobial and toxicity evaluation of bioceramic based ofloxacin loaded biodegradable microspheres for periodontal infection. Current drug delivery. 2012;9(5):515-526.
5. Vashisth P, Raghuwanshi N, Srivastava AK, Singh H, Nagar H, Pruthi V. Ofloxacin loaded gellan/PVA nanofibers-Synthesis, characterization and evaluation of their gastroretentive/mucoadhesive drug delivery potential. Materials Science and Engineering: C. 2017;71:611-619.
6. Parveen N, Singh S. Lipoidalnanoparticulate drug delivery of ofloxacin for ocular use. World J. Pharm. Res. 2017;7:1006-1025.
7. Pasupuleti C, Mohammad AS, Rasheed N, Umadevi K, Adilakshmi D. Simultaneous Formulation, Estimation and Evaluation of Ofloxacin Microbeads. Asian Journal of Pharmaceutical Analysis. 2016;6(3):167-182.
8. Rather MA, Amin S, Maqbool M, Bhat ZS, Gupta PN, Ahmad Z. Preparation and *in vitro* characterization of albumin nanoparticles encapsulating an anti-tuberculosis drug-levofloxacin. Advanced Science, Engineering and Medicine. 2016;8(11):912-917.
9. Kumar SP, Arivuchelvan A, Jagadeeswaran A, Punniamurthy N, Selvaraj P, Jagatheesan RPN, *et al*. Formulation of enrofloxacin SLNs and its pharmacokinetics in emu (Dromaiusnovaehollandiae) birds. Applied Nanoscience. 2015;5:661-671.
10. Harsha S, Chandramouli R, Rani S. Ofloxacin targeting to lungs by way of microspheres. International journal of pharmaceutics. 2009;380(1-2):127-132.
11. Babu Natarajan S, Lakshmanan P. Effect of processing variables on characterization of ofloxacin loaded lipospheres prepared by melt dispersion technique. Current Drug Delivery. 2013;10(5):517-526.
12. Kumar YV, Jeganath S, Babu DV. Design, Formulation and Characterization of Ofloxacin Nanospheres.
13. Karatas A, Boluk A, HilalAlgan A. Poloxamer/Chitosan in situ gelling system for ocular delivery of ofloxacin. Current Drug Therapy. 2014;9(4):219-25.